Search

Your search keyword '"Jinal N. Bhiman"' showing total 83 results

Search Constraints

Start Over You searched for: Author "Jinal N. Bhiman" Remove constraint Author: "Jinal N. Bhiman"
83 results on '"Jinal N. Bhiman"'

Search Results

1. Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection

2. Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level

3. Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021

4. SARS-CoV-2 genomic surveillance in wastewater as a model for monitoring evolution of endemic viruses

5. Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants

6. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

7. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa

8. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa

9. SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa

10. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

11. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)

12. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021

13. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation

14. A genomics network established to respond rapidly to public health threats in South Africa

15. Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization

16. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity

17. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020–2021: A Case-Ascertained, Prospective, Observational Household Transmission Study

18. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21

19. T cell responses to SARS-CoV-2 spike cross-recognize Omicron

20. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021

21. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

22. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study

23. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa

24. SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts

25. Risk factors for severe COVID-19 among HIV-infected and-uninfected individuals in South Africa, April 2020- March 2022 – data from sentinel surveillance

26. Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

27. SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1

28. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

29. An early warning system for emerging SARS-CoV-2 variants

30. Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function

31. Detection of a SARS-CoV-2 variant of concern in South Africa

32. Omicron infection enhances Delta antibody immunity in vaccinated persons

33. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse

34. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa

35. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

36. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virus-Infected and Uninfected Persons: A Cross-Sectional Household Survey

37. A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa

38. Reduced amplification efficiency of the RNA-dependent-RNA-polymerase (RdRp) target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests

39. Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa

40. Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern

41. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021

42. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens

43. Genomic epidemiology of SARS-CoV-2 in Mauritius reveals a new wave of infections dominated by the B.1.1.318, a variant under investigation

44. Longitudinal SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, during the first and second waves July 2020-March 2021

45. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

46. Author Correction: T cell responses to SARS-CoV-2 spike cross-recognize Omicron

47. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity

48. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

49. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

50. Sixteen novel lineages of SARS-CoV-2 in South Africa

Catalog

Books, media, physical & digital resources